Metabolic reprogramming and genome instability represent two fundamental hallmarks of cancer. Emerging studies now demonstrate that specific metabolic alterations directly fuel replication stress, DNA damage, and compromised DNA damage response. This underscores that metabolites are not merely passive by-products but active biochemical regulators of genome instability. Perturbation of specific metabolic pathways can preferentially unmask these vulnerabilities for therapeutic targeting. In this review, we propose an integrated framework highlighting metabolism-induced genome instability as a potential therapeutic target. By delineating the metabolic targets that induce genome instability, we provide a comprehensive overview of the complex interplay between metabolic pathways and genome stability. We further highlight that metabolism-induced genome instability can be strategically exploited to potentiate standard-of-care therapies. Collectively, these insights redefine metabolism-induced genome instability as a targetable vulnerability of cancer. This systematic synthesis provides a mechanistic rationale for next-generation therapeutic designs in which metabolic interventions are leveraged to convert genome instability into actionable clinical vulnerabilities.
Keywords: Cancer metabolism, Cancer therapy, DNA damage response, DNA repair, Genome instability, Therapeutic resistance
Experimental hematology & oncology
Journal Article
English
42001172
Guideline Central and select third party use “cookies” on this website to enhance the user experience.
This technology helps us gather statistical and analytical information to optimize the relevant content for you.
The user also has the option to opt-out which may have an effect on the browsing experience.